Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients
Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients
复制标题
DOI：
10.3109/10428194.2013.776165
复制
发表时间：
2013-11-01
影响因子：
2.6
通讯作者：
Brice, Pauline
中科院分区：
文献类型：
--
作者：
Ghesquieres, Herve;Stamatoullas, Aspasia;Brice, Pauline
有限的数据支持在霍奇金淋巴瘤（HL）中使用苯达莫司汀。这项回顾性研究评价了苯达莫司汀在28例难治性HL或自体干细胞移植（ASCT）后复发性HL患者中的疗效和毒性，作为同情使用计划的一部分。苯达莫司汀治疗前的中位治疗次数为5（3-8）。ASCT和非清髓性同种异体移植之前分别为25例和6例患者进行。苯达莫司汀给药周期的中位数为3（1-12）。客观缓解率为50%，29%的患者完全缓解（CR）。中位无进展生存期为5.7个月，CR患者为10.2个月。在前6个周期内，2例患者发生发热性中性粒细胞减少症，4例患者发生3-4级血小板减少症。苯达莫司汀在这些高度预治疗的HL患者中有效。它可能在HL的治疗策略中早期使用，并与其他活性药物联合使用。
Limited data support the use of bendamustine in Hodgkin lymphoma (HL). This retrospective study evaluated the efficacy and toxicity of bendamustine in 28 patients with refractory HL or relapsed HL after autologous stem cell transplant (ASCT) used as part of a compassionate use program. The median number of therapies before bendamustine was 5 (3-8). ASCT and non-myeloablative allogeneic transplant were previously performed for 25 and six patients, respectively. The median number of bendamustine cycles administered was 3 (1-12). The objective response rate was 50% with complete response (CR) in 29% of patients. The median progression-free survival was 5.7 months, and 10.2 months in patients with CR. During the first six cycles, two patients had a febrile neutropenia and four patients had grade 3-4 thrombocytopenia. Bendamustine was effective in these highly pretreated patients with HL. It might be used earlier in the treatment strategy of HL and in combination with other active drugs.